Taisho Pharmaceutical Co., Ltd.

Canon Kabushiki Kaisha

Other

Nissan Chemical Industries Limited

Nihon Nohyaku Co., Ltd.

Taketoshi Okubo

Atsuro Nakazato

Kazuyuki Tomisawa

Toshihito Kumagai

Shigeyuki Chaki

Dai Nozawa

Tomoko Tamita

Ludo E J Kennis

Masanori Yoshida

Masashi Nagamine

Shoji Koike

Kenichi Iida

Toshio Nakamura

Makoto Gotoh

Atsuhito Yoshizawa

Kenji Yamamoto

Takaaki Ishii

Ikuo Nakazawa

Masayuki Ikegami

Akira Kuriyama

Yoshinori Sekiguchi

Yuri Amada

Koichiro Harada

Marcel F L De Bruyn

Jean-Pierre A M Bongartz

Frans M A Van Den Keybus

Yves E M Van Roosbroeck

Marcel G M Luyckx

Robert J M Hendrickx

Mikako Yamaguchi

Ludo Ej Kennis

Ludo E Kennis

Takeshi Miyazaki

Hiroshi Ohta

Hideo Tanaka

Tsuyoshi Shibata

Toshio Tanaka

Masashi Hirose

Taichi Shintou

Tsuyoshi Nomoto

Kohei Watanabe

Masato Hayashi

Shuji Yamamoto

Kazuya Kameo

Yasuhito Shimada

Takanori Shimizu

Yuhei Nishimura

Shigeru Okuyama

Takeshi Kuwada

Norihiro Nishimura

Kumi Abe

Xiang-Min Sun

Takeshi Koami

Shigetada Sasako

Tomoko Ishizaka

Takayuki Nagatsuka

Izumi Aibe

Shin-ichi Ogawa

Kuniaki Kondoh

Jean-Pierre A Bongartz

Frans M Van Den Keybus

Yves E Van Roosbroeck

Robert J Hendrickx

Marcel F De Bruyn

Marcel G Luyckx

A metallic image forming method is a method for forming a metallic image with a metallic ink containing an organic coloring agent capable of exhibiting a metallic color on a recording medium provided with an undercoat layer thereon having a black color or an opposite color to the color of diffused light from the metallic ink. The method includes applying the metallic ink onto the recording medium so as to cover at least part of the undercoat layer.

Metallic image forming method

Provided is a metallic image forming method by which a metallic image that assumes sufficient metallic feeling can be acquired. The metallic image forming method is a method of forming a metallic image on a recording medium through use of an ink containing metal particles and includes an ink application step of applying an ink onto a recording medium having an underlayer formed thereon such that the ink overlaps at least a part of the underlayer, the underlayer having a black color or an opposite color with respect to diffusion light of the ink.

Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I). 

Probe for a biological specimen and labelling method and screening method using the probe

Aspects of the present invention provide an ink-jet recording method including the step of applying an ink to a recording medium by discharging the ink from a recording head by action of thermal energy and the step of fixing the ink to the recording medium by heating the ink applied to the recording medium. The ink contains water, a self-dispersing pigment, and resin particles. The resin particles have a glass transition temperature of not less than 25&#xb0; C., an average particle diameter of 70 nm or more and 220 nm or less, and an acid value of 25 mg KOH/g or more and 150 mg KOH/g or less.

Ink-jet recording method

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. 

Pyrrolopyridine derivatives substituted with cyclic amino group

The invention provides an ink jet recording ink containing a self-dispersion pigment to a surface of which an anionic functional group represented by the following general formula (1) is bonded directly or through another atomic group, an ammonium salt of an organic carboxylic acid, water, and a water-soluble compound having a hydrophilicity-hydrophobicity coefficient of 0.26 or more as defined by the following equation (A), the ink having a surface tension of 34 mN/m or less, wherein Mand Mare, independently of each other, a hydrogen atom, alkali metal, ammonium or organic ammonium;Hydrophilicity-hydrophobicity coefficient=[(Water activity of a 20% aqueous solution)&#x2212;(Molar fraction of water in the 20% aqueous solution)]/[1&#x2212;(Molar fraction of water in the 20% aqueous solution)]&#x2003;&#x2003;(A).

Ink jet recording ink, ink jet image forming method and ink jet recording apparatus

An inkjet recording ink having a surface tension of 34 mN/m or more is provided. The inkjet recording ink contains an anionic self-dispersion pigment having an anionic functional group, a salt, and a water-soluble compound having a hydrophilicity/hydrophobicity coefficient of 0.26 or more. The ink contains a larger amount of cesium ion than the amount of the anionic functional group. The hydrophilicity/hydrophobicity coefficient is defined by equation (A).

Inkjet recording ink

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. 

Pyrrolopyrimidine and pyrrolotriazine derivatives

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MCreceptor antagonistic effect.

Aminopyrrolidine compound

It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle

[PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for &#x3b4; receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following a [I] has a high affinity for CRF receptors and/or &#x3b4; receptors, and is effective against diseases in which CRF is considered to be involved.

Pyrrolo[2,3-D]pyrimidine derivatives substituted with a cyclic amino group

Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved 

Triaza-cyclopenta[cd]indene derivatives

There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MCreceptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]:[wherein Aris a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Aris a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula:(wherein Ris a hydrogen atom or a halogen atom; and X&#x2014;Y is CH&#x2014;NH, CH&#x2014;O, CH&#x2014;S or N&#x2014;O) or a group represented by the formula:(wherein Ris a hydrogen atom, a hydroxyl group or a Calkoxy group); Ris a hydrogen atom, a Calkyl group, a Ccycloalkyl group, a Calkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; Rand Rare the same or different, and are each a hydrogen atom or a Calkyl group; A-B is N&#x2014;CH, CH&#x2014;CH, C(OH)&#x2014;CHor C&#x2550;CH; Tis a single bond, &#x2014;N(R)&#x2014; (wherein Ris a hydrogen atom or a Calkyl group), &#x2014;O&#x2014;, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C(&#x2550;O)&#x2014;; n is an integer of from 1 to 10 and when Tis a single bond, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C(&#x2550;O)&#x2014;, n is an integer of from 2 to 10 when Tis &#x2014;N(R)&#x2014; or &#x2014;O&#x2014;], or a pharmaceutically acceptable salt thereof.

Remedial agent for anxiety neurosis or depression and piperazine derivative

Growing community of inventors

Tokyo, Japan

Taketoshi Okubo